Susha Cheriyedath

Feature Writer

B.Sc Chemistry, M.Sc. Biochemistry

Susha is a scientific communication professional holding a Master's degree in Biochemistry, with expertise in Microbiology, Physiology, Biotechnology, and Nutrition. After a two-year tenure as a lecturer from 2000 to 2002, where she mentored undergraduates studying Biochemistry, she transitioned into editorial roles within scientific publishing. She has accumulated nearly two decades of experience in medical communication, assuming diverse roles in research, writing, editing, and editorial management.

Passionate about health and nutrition, Susha is interested in various diet types, such as veganism, and their impact on the body and metabolism. She remains dedicated to staying current with the latest developments in the medical and health science fields. In her leisure time, she engages in gardening, cooking/baking, and sketching/painting. When not immersed in work, she can often be found tending to her garden (weather permitting) or engrossed in her sketching and painting projects.

See less

Articles from Susha

Combating the fourth wave of COVID-19 in Ontario

Researchers from Canada recently attempted to project the number of COVID-19 cases and the demand for acute hospital resources for Fall 2021 in a mid-sized southwestern Ontario community. They sought to evaluate if current vaccine coverage and contact reduction levels are sufficient to mitigate a possible 4th wave driven by the Delta variant, or if stricter public health measures need to be reinstituted.

8 Sep 2021

Is the SARS-CoV-2 Lambda variant more vaccine-resistant than the Delta variant?

Researchers in the USA and China recently published a report in which they discussed the potential factors that confer high infectivity and immune resistance on the Delta and Lambda variants.

6 Sep 2021

Polymeric and lipid nanoparticles in self-amplifying RNA vaccines result in higher protein expression and immunogenicity

Self-amplifying RNA (saRNA) is an advanced platform for nucleic acid vaccine development. The backbone is typically derived from an alphaviral genome and encodes a gene of interest (GOI) and a viral replicase that can amplify the genomic and subgenomic RNA.

30 Aug 2021

Modeling of COVID-19 seroprevalence and resurgence in Canada

Despite increased vaccine distribution and a significant decrease in the number of COVID-19 cases in Canada, the future of the pandemic is still a major concern, based on the possibility of a resurgence in the short term as well as long term and an understanding of the future of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity. It is not clear if the Canadian population will reach herd immunity or if there is a risk of future resurgence of the virus in the Fall or Winter.

30 Aug 2021

Could soluble CD24 offer some hope against severe COVID-19?

A recent randomized phase III trial conducted by researchers at the Ohio State University, Columbus, OH, US, evaluated the impact of CD24Fc in severe COVID-19 patients and showed promising clinical efficacy. This study is available as a preprint on the medRxiv* server.

26 Aug 2021

Study shows impaired SARS-CoV-2 mRNA vaccine antibody response in individuals with chronic conditions

A recent study in Colorado used real-world data to evaluate if individuals with chronic conditions have reduced antibody response to COVID-19 mRNA vaccines. The study investigated whether some medical conditions may impact antibody response to the mRNA vaccines.

9 Aug 2021

Controlling the spread of SARS-CoV-2 at a large public university

Researchers from the U.S. recently reported a multimodal "SHIELD: Target, Test, and Tell" program that helped mitigate the transmission of SARS-CoV-2 at a large public university. The program also prevented community transmission and helped the continuation of in-person classes during the pandemic. This study is available on the medRxiv* preprint server.

9 Aug 2021

Is it possible to identify pre-symptomatic and asymptomatic COVID-19 clinically?

The COVID-19 pandemic has severely impacted morbidity and mortality in nursing home residents across the world. Earlier detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may help better mitigate the risk of viral transmission. As both pre-symptomatic and asymptomatic transmission is common in these outbreaks, screening for threshold temperatures of 38°C or higher could miss timely detection in most infected people.

29 Jul 2021

SARS-CoV-2 Beta variant marginally affects Pfizer vaccination efficacy in fully vaccinated

Researchers from Israel recently evaluated the efficacy of the Pfizer vaccine against the SARS-CoV-2 B.1.351 variant.

28 Jul 2021

SARS-CoV-2 variants show distinct humoral response and transcriptional profiles in hamster model

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel, highly infectious respiratory virus, and the causative agent of coronavirus disease 2019 (COVID-19) pandemic. SARS-CoV-2, which first originated in Wuhan, in Hubei province of China, is a member of the Coronavirdae family and has a large, non-segmented RNA genome.

14 Jul 2021